At the news
? NEUTRALIMPACT 6/10 8-K filed Nov 9, 2026 at 07:49 ET
CorMedix entered into a loan agreement with BioPharma Credit for up to $50M in term loans to fund the acquisition of four commercial-stage products (Cinvanti, Zynrelef, Aponvie, Sustol) from Heron Therapeutics. The transaction includes a $145M cash component plus 14.58M shares of CorMedix common stock, with the loan secured by substantially all assets. The combined financing and acquisition significantly increases CorMedix's leverage and adds four marketed products to its portfolio.
- Loan agreement for up to $50M in term loans (Tranche A and Tranche B) from BioPharma Credit lenders
- Proceeds used to fund acquisition of Heron Therapeutics products: Cinvanti, Zynrelef, Aponvie, Sustol
- Asset purchase agreement with Heron: $145M base cash consideration plus 14,583,333 shares of CorMedix common stock
- Loan interest rate is Term SOFR plus 5.75% per annum, with quarterly payments starting ~3 years after closing
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access